Collaborating with experienced service providers can help streamline this process while removing potential hurdles, allowing for a seamless transition from discovery into clinical development. Charles River and Quotient Sciences can help you accelerate your path to the clinic with an integrated offering that bridges molecules from early discovery to clinical proof of concept.
Charles River brings deep expertise in medicinal chemistry, biology, DMPK, early pharmaceutics, and non-clinical safety, which when coupled with Quotient Sciences’ expert knowledge of drug substance synthesis, drug product development and manufacturing, and clinical testing creates a solution under a single program of work. Together, we'll provide a full set of deliverables to get your molecule “clinic ready” and help improve your chances of clinical success.
Combined, Charles River and Quotient Sciences bring to your program more than a century of experience in drug development and knowledge from our work on thousands of molecules across all stages of development. A tight integration of activities between two trusted companies streamlines the outsourcing model and improves decision-making, problem-solving, and technology transfer.
Fill out the form below to receive a copy of our info sheet and schedule a time to talk with our team.
Join experts from Charles River and Quotient Sciences for a complimentary lunch seminar during AAPS PharmSci360 on Tuesday, October 18. Speakers from both companies will co-present Integrated Strategies for Accelerating from Discovery to IND and Beyond and will be available for Q&A and networking following the presentation.